IP Library Granted Patent US 8,647,626
Granted Patent B2
US 8,647,626 · App. 13/912,569 · Granted Feb 11, 2014

Compositions comprising TNF-specific antibodies for oral delivery

Inventor: Barbara S. Fox (Wayland, MA)
Assignee: Avaxia Biologics, Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,647,626
App. No.
13/912,569
Granted
Feb 11, 2014
Kind
B2
Abstract

In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract.

Claims (6)

1. A composition for oral delivery to a human patient comprising polyclonal antibodies specific to TNF, wherein the antibodies are obtained from the milk or colostrum of a ruminant that has been immunized with TNF or any antigenic fragment thereof, and wherein upon oral administration to the digestive tract of the patient, the composition is therapeutically effective to treat inflammatory bowel disease in the patient, and wherein the antibodies specific to TNF are present in the composition at a dosage of about 1 mg per day to about 1 gram per day.

2. The composition of claim 1 formulated as a solid dosage form for oral administration.

3. The composition of claim 2 wherein the solid dosage form is selected from capsules, tablets, pills powders and granules.

4. The composition of claim 2 wherein the solid dosage form comprises an enteric coating.

5. The composition of claim 1 wherein the ruminant is a bovine.

6. A method of treating inflammatory bowel disease in a human patient in need thereof comprising orally administering to a patient, a composition of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: PMCM2, LLC
To: CIRCLE 33, LLC
Reel/Frame 038655/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: AVAXIA BIOLOGICS, INC
To: PMCM2, LLC
Reel/Frame 038642/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2013
From: FOX, BARBARA S.
To: AVAXIA BIOLOGICS, INCORPORATED
Reel/Frame 031185/0228 →
Continuity (8)
Continuation 13860029 · Apr 10, 2013
Division 13452026 · Apr 20, 2012
Division 12753438 · Apr 2, 2010
Continuation PCTUS2008078543 · Oct 2, 2008
Provisional Application 61055215 · May 22, 2008
Provisional Application 61015507 · Dec 20, 2007
Provisional Application 60976876 · Oct 2, 2007
Related Publication 20130337018A1 · Dec 19, 2013